Search Results - "Swigris, J."

Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials by Noble, Paul W, Albera, Carlo, Bradford, Williamson Z, Costabel, Ulrich, du Bois, Roland M, Fagan, Elizabeth A, Fishman, Robert S, Glaspole, Ian, Glassberg, Marilyn K, Lancaster, Lisa, Lederer, David J, Leff, Jonathan A, Nathan, Steven D, Pereira, Carlos A, Swigris, Jeffrey J, Valeyre, Dominique, King, Jr, Talmadge E

“…Pirfenidone is an antifibrotic agent that has been evaluated in three multinational phase 3 trials in patients with idiopathic pulmonary fibrosis (IPF). We…”
Get full text

Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease by Solomon, Joshua J, Chung, Jonathan H, Cosgrove, Gregory P, Demoruelle, M Kristen, Fernandez-Perez, Evans R, Fischer, Aryeh, Frankel, Stephen K, Hobbs, Stephen B, Huie, Tristan J, Ketzer, Jill, Mannina, Amar, Olson, Amy L, Russell, Gloria, Tsuchiya, Yutaka, Yunt, Zulma X, Zelarney, Pearlanne T, Brown, Kevin K, Swigris, Jeffrey J

“…Interstitial lung disease (ILD) is a common pulmonary manifestation of rheumatoid arthritis. There is lack of clarity around predictors of mortality and…”
Get full text

The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference by Swigris, Jeffrey J, Wamboldt, Frederick S, Behr, Juergen, du Bois, Roland M, King, Talmadge E, Raghu, Ganesh, Brown, Kevin K

“…The response characteristics of the 6 minute walk test (6MWT) in studies of idiopathic pulmonary fibrosis (IPF) are only poorly understood, and the change in…”
Get more information

Rheumatoid Arthritis―Interstitial Lung Disease―associated Mortality by OLSON, Amy L, SWIGRIS, Jeffrey J, SPRUNGER, David B, FISCHER, Aryeh, FERNANDEZ-PEREZ, Evans R, SOLOMON, Josh, MURPHY, James, COHEN, Marc, RAGHU, Ganesh, BROWN, Kevin K

“…Mortality rates from rheumatoid arthritis-associated interstitial lung disease (RA-ILD) are largely unknown. We sought to determine mortality rates from…”
Get full text

Mycophenolate Mofetil Improves Lung Function in Connective Tissue Disease-associated Interstitial Lung Disease by FISCHER, Aryeh, BROWN, Kevin K, SOLOMON, Joshua J, SWIGRIS, Jeffrey J, DU BOIS, Roland M, FRANKEL, Stephen K, COSGROVE, Gregory P, FERNANDEZ-PEREZ, Evans R, HUIE, Tristan J, KRISHNAMOORTHY, Mahalakshmi, MEEHAN, Richard T, OLSON, Amy L

“…Small series suggest mycophenolate mofetil (MMF) is well tolerated and may be an effective therapy for connective tissue disease-associated interstitial lung…”
Get full text

Sarcoidosis-related Mortality in the United States from 1988 to 2007 by SWIGRIS, Jeffrey J, OLSON, Amy L, HUIE, Tristan J, FERNANDEZ-PEREZ, Evans R, SOLOMON, Joshua, SPRUNGER, David, BROWN, Kevin K

“…It has been nearly 20 years since sarcoidosis mortality was examined at the population level in the United States. To examine mortality rates and underlying…”
Get full text

Health-related quality of life in patients with idiopathic pulmonary fibrosis: a systematic review by Swigris, J J, Kuschner, W G, Jacobs, S S, Wilson, S R, Gould, M K

“…Background: Idiopathic pulmonary fibrosis (IPF) profoundly affects the quality of patients’ lives. A systematic review was performed to evaluate critically the…”
Get full text

Identifying an Inciting Antigen Is Associated With Improved Survival in Patients With Chronic Hypersensitivity Pneumonitis by Fernández Pérez, Evans R., MD, FCCP, Swigris, Jeffrey J., DO, FCCP, Forssén, Anna V., MS, Tourin, Olga, MD, Solomon, Joshua J., MD, FCCP, Huie, Tristan J., MD, FCCP, Olson, Amy L., MD, MSPH, Brown, Kevin K., MD, FCCP

“…Background The cornerstone of hypersensitivity pneumonitis (HP) management is having patients avoid the inciting antigen (IA). Often, despite an exhaustive…”
Get full text

A Multidisciplinary Evaluation Helps Identify the Antisynthetase Syndrome in Patients Presenting as Idiopathic Interstitial Pneumonia by Chartrand, Sandra, Swigris, Jeffrey J, Peykova, Lina, Chung, Jonathan, Fischer, Aryeh

“…Interstitial lung disease (ILD) is 1 possible manifestation of the idiopathic inflammatory myopathies (IIM). Occasionally, patients presenting with ILD are…”
Get full text

The Clinical Course of Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia by Carr, Laurie L., MD, Chung, Jonathan H., MD, Duarte Achcar, Rosane, MD, Lesic, Zoran, MD, Rho, Ji Y., MD, Yagihashi, Kunihiro, MD, Tate, Robert M., MD, Swigris, Jeffrey J., DO, Kern, Jeffrey A., MD

“…BACKGROUND Current understanding of the clinical course of diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) is poor and based…”
Get full text

Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis by Nathan, Steven D, Prof, Albera, Carlo, MD, Bradford, Williamson Z, MD, Costabel, Ulrich, Prof, Glaspole, Ian, MD, Glassberg, Marilyn K, Prof, Kardatzke, David R, PhD, Daigl, Monica, MSc, Kirchgaessler, Klaus-Uwe, MD, Lancaster, Lisa H, MD, Lederer, David J, MD, Pereira, Carlos A, Prof, Swigris, Jeffrey J, MD, Valeyre, Dominique, Prof, Noble, Paul W, MD

“…Summary Background In clinical trials of idiopathic pulmonary fibrosis, rates of all-cause mortality are low. Thus prospective mortality trials are…”
Get full text

High resolution computed tomography pattern of usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease: Relationship to survival by Yunt, Zulma X., MD, Chung, Jonathan H., MD, Hobbs, Stephen, MD, Fernandez-Perez, Evans R., MD, MS, Olson, Amy L., MD, MSPH, Huie, Tristan J., MD, Keith, Rebecca C., MD, Janssen, William J., MD, Goldstein, Barbara L., MD, Lynch, David A., MD, Brown, Kevin K., MD, Swigris, Jeffrey J., DO, MS, Solomon, Joshua J., MD

“…Abstract Purpose Interstitial lung disease is a common extra-articular manifestation of rheumatoid arthritis (RA-ILD) and is associated with significant…”
Get full text

Mortality from Pulmonary Fibrosis Increased in the United States from 1992 to 2003 by Olson, Amy L, Swigris, Jeffrey J, Lezotte, Dennis C, Norris, Jill M, Wilson, Carla G, Brown, Kevin K

“…From the late 1970s to the early 1990s, studies found that mortality rates for pulmonary fibrosis were increasing. Recent data for mortality from pulmonary…”
Get full text

Pulmonary Function and Survival in Idiopathic vs Secondary Usual Interstitial Pneumonia by Strand, Matthew J., PhD, Sprunger, David, MD, Cosgrove, Gregory P., MD, FCCP, Fernandez-Perez, Evans R., MD, MPH, FCCP, Frankel, Stephen K., MD, FCCP, Huie, Tristan J., MD, FCCP, Olson, Amy L., MD, MSPH, Solomon, Joshua, MD, FCCP, Brown, Kevin K., MD, FCCP, Swigris, Jeffrey J., DO

“…BACKGROUND The usual interstitial pneumonia (UIP) pattern of lung injury may occur in the setting of connective tissue disease (CTD), but it is most commonly…”
Get full text

Pulmonary fibrosis is associated with an elevated risk of thromboembolic disease by SPRUNGER, D. B, OLSON, A. L, HUIE, T. J, FERNANDEZ-PEREZ, E. R, FISCHER, A, SOLOMON, J. J, BROWN, K. K, SWIGRIS, J. J

“…Recent epidemiological studies have suggested an increased risk of venous thromboembolism (VTE) in lung fibrosis. Large-scale epidemiological data regarding…”
Get full text

The SF-36 and SGRQ: Validity and first look at minimum important differences in IPF by Swigris, Jeffrey J, Brown, Kevin K, Behr, Juergen, du Bois, Roland M, King, Talmadge E, Raghu, Ganesh, Wamboldt, Frederick S

“…Summary Rationale Health-related quality of life (HRQL) is an important outcome in drug trials. Little is known about how the Short Form-36 (SF-36) and Saint…”
Get full text

A first look at the reliability, validity and responsiveness of L-PF-35 dyspnea domain scores in fibrotic hypersensitivity pneumonitis by Swigris, Jeffrey J, Aronson, Kerri, R Fernández Pérez, Evans

“…Dyspnea impairs quality of life (QOL) in patients with fibrotic hypersensitivity pneumonitis (FHP). The Living with Pulmonary Fibrosis questionnaire (L-PF)…”
Get full text

Patients' perceptions and patient-reported outcomes in progressive-fibrosing interstitial lung diseases by Swigris, Jeffrey J, Brown, Kevin K, Abdulqawi, Rayid, Buch, Ketan, Dilling, Daniel F, Koschel, Dirk, Thavarajah, Krishna, Tomic, Rade, Inoue, Yoshikazu

“…The effects of interstitial lung disease (ILD) create a significant burden on patients, unsettling almost every domain of their lives, disrupting their…”
Get full text

Patient-Reported Outcomes in Idiopathic Pulmonary Fibrosis Research by Swigris, Jeffrey J., DO, Fairclough, Diane, DrPH

“…Patient-reported outcomes (PROs) include questionnaires or surveys that ask patients for their perceptions about things like symptoms they are experiencing or…”
Get full text

Understanding the determinants of health-related quality of life in rheumatoid arthritis-associated interstitial lung disease by Natalini, Jake G., M.D, Swigris, Jeff J., D.O., M.S, Morisset, Julie, M.D, Elicker, Brett M., M.D, Jones, Kirk D., M.D, Fischer, Aryeh, M.D, Collard, Harold R., M.D, Lee, Joyce S., M.D

“…Abstract Rationale Health-related quality of life (HRQL) is impaired among patients with interstitial lung disease (ILD). Little is understood about HRQL in…”
Get full text